Basel Cannabis Study Shows Mental Health Benefits

In a pioneering move for Swiss drug policy research, Basel's two-year 'Weedcare' study has revealed significant positive outcomes in participants' mental health. The groundbreaking research, which marks Switzerland's first legal recreational cannabis trial, has demonstrated that regulated cannabis access can coexist with stable consumption patterns while potentially offering mental health benefits.

The Weedcare project, led by Basel City's Department of Health in collaboration with University Psychiatric Clinics Basel, Psychiatric Services Aargau, and the University of Basel, enrolled 300 adult participants who were existing cannabis users. The study implemented a controlled distribution system through local pharmacies, offering cannabis products with varying THC levels, including options below 13% THC - notably lower than typical black market concentrations.

The most significant findings from the study center on mental health improvements among participants. The Basel City's Department of Health reported marked decreases in depressive symptoms and anxiety levels over the two-year period. Importantly, these improvements occurred while consumption patterns remained stable, with no increase in either frequency of use or quantity consumed. The study also noted reduced addictive behaviors among participants.

Throughout the study period, 87 kilograms of cannabis were distributed, representing approximately CHF 900,000 in market value. The regulated pricing structure maintained costs between CHF 8-12 per gram, establishing a competitive alternative to illegal market options. One-third of all products sold featured THC content below 13%, demonstrating consumer interest in lower-potency options not typically available through unregulated channels.

Set to continue until January 2027, the Basel study's positive interim results are already influencing Switzerland's approach to cannabis regulation. Similar trials have been initiated in other major Swiss cities, including Zurich, Lausanne, Bern, Biel, and Lucerne. These findings contribute valuable data to ongoing policy discussions, as Switzerland carefully considers potential paths toward regulated cannabis access. The study's success in maintaining stable consumption while improving mental health outcomes provides compelling evidence for policymakers considering regulatory reforms.